Azenta Inc.

Azenta Inc. Earnings Recaps

AZTA Health Care 3 recaps
Q2 2026 May 7, 2026

Azenta's shares dropped 24.5% following the Q2 report as investors were disappointed by organic revenue decline, margin compression, and a cautious full-year outlook amid execution challenges and soft demand, particularly in North America.

Key takeaways
  • Organic revenue decreased 3% year-over-year in Q2, driven by weakened demand in North America and competitive pressures in Multiomics.
  • Adjusted EBITDA margin fell to 5.4%, below expectations, reflecting lower volumes and operational inefficiencies.
  • Continued strength was seen in recurring revenue areas, including sample repository solutions, product services, consumables, and instruments.
  • Softness persisted in automated and cryogenic store systems, with ongoing quality remediation delays expected to extend into Q3.
  • Fiscal 2026 guidance was lowered to organic revenue growth between -2% and +1%, with adjusted EBITDA estimated down 125 basis points to flat, citing prolonged capital deployment constraints and cautious demand.
Full recap
Q1 2026 Feb 4, 2026

Azenta, Inc. reported a first-quarter organic revenue decline of approximately 1% as anticipated, navigating a mixed macro environment while laying the groundwork for future growth and operational improvements.

Key takeaways
  • Consistent execution across teams is driving progress, positioning Azenta for a successful turnaround amid cautious capital spending in the life sciences sector.
  • Bookings were impacted by weak capital investments and a government shutdown, but the company expects future order recognition to stabilize full-year results.
  • The strategic focus for 2026 includes enhancing operational excellence, accelerating growth, and disciplined capital deployment to create long-term shareholder value.
Full recap
Q4 2025 Nov 21, 2025

Azenta, Inc. reported a solid Q4 2025, achieving 3% core revenue growth and a notable 310 basis points increase in margins, highlighting the company's commitment to operational excellence amid macroeconomic challenges.

Key takeaways
  • Successfully implemented the Azenta Business System, driving improvements in quality and on-time delivery while fostering a culture of operational excellence.
  • Maintained a strong balance sheet with over $500 million in cash and equivalents, providing flexibility for disciplined investments and share repurchases.
  • Positioned for continued growth with an expected core revenue growth of 3% to 5% and adjusted EBITDA margin expansion of 300 basis points for FY 2026.
  • Evolved commercial organization with enhanced leadership and an expanded field presence to accelerate growth in a competitive market.
  • Confident in navigating ongoing macroeconomic uncertainties while capitalizing on new partnership opportunities in sample management and automation.
Full recap